Predicting etoposide toxicity: Relationship to organ function and protein binding

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 257-267

  Joel, S P ^a   Shah, R ^a   Clark, P I ^a   Slevin, M L ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PROTEIN BINDING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL;

EID: 0030030354     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.257     Document Type: Article

References (16)

1. Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333-1340, 1989
2. Johnson DH, Greco FA, Strupp J, et al: Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: A phase II trial. J Clin Oncol 8:1613-1617, 1990
3. Smit EF, Carney DN, Harford P, et al: A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 44:631-633, 1989
4. Hainsworth JD, Johnson DH, Greco FA: Chronic etoposide schedules in the treatment of non-Hodgkin's lymphoma. Semin Oncol 19:13-18, 1992 (suppl 14)
5. Arbuck SG, Douglass HO, Crom WR, et al: Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 4:1690-1695, 1986
6. D'Incalci M, Rossi C, Zucchetti M, et al: Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 46:2566-2571, 1986
7. Hande KR, Wolff SN, Greco FA, et al: Etoposide kinetics in patients with obstructive jaundice [see comments]. J Clin Oncol 8:1101-1107, 1990
8. Stewart CF, Arbuck SG, Fleming RA, et al: Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 50:385-393, 1991
9. Creaven PJ: The clinical pharmacology of etoposide (VP-16) in adults, in Issell BF, Mauggia FM, Carter SK (eds): Etoposide (VP16): Current Status and New Developments. San Diego, CA, Academic, 1984, pp 103-114
10. 14C etoposide in man. Br J Cancer 69:49, 1994 (suppl 21; abstr)
11. Clark PI, Slevin ML, Joel SP, et al: A randomized trial of two etoposide schedules in small-cell lung cancer: The influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12:1427-1435, 1994
12. Harvey VJ, Joel SP, Johnston A, et al: High-performance liquid chromatography of etoposide in plasma and urine. J Chromatogr 339:419-423, 1985
13. Johnston A, Woolard RC: STRIPE: An interactive computer programme for the analysis of drug pharmacokinetics. J Pharmacol Methods 9:193-199, 1983
14. Grochow LB, Baraldi C, Noe D: Is dose normalization to weight or body surface area useful in adults? J Natl Can Inst 82:323-325, 1990
15. Stewart CF, Fleming RA, Arbuck SG, et al: Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients. Cancer Res 50:6854-6859, 1990
16. Lowis SP, Pearson ADJ, Newell DR, et al: Etoposide pharmacokinetics in children. Br J Cancer 65:43, 1992 (suppl 16; abstr)